DBV TECHNOLOGIES SA (DBV.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:DBV - FR0010417345 - Common Stock
DBV.PA Key Statistics, Chart & Performance
The current stock price of DBV.PA is 2.285 EUR. In the past month the price decreased by -0.99%. In the past year, price increased by 273.13%.
DBV.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.33 | 49.11B | ||
| ARGX.BR | ARGENX SE | 72.92 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.38B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.64B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.79B | ||
| 5CV.DE | CUREVAC NV | 5.36 | 1.05B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 532.39M | ||
| ALCLS.PA | CELLECTIS | N/A | 445.95M | ||
| FYB.DE | FORMYCON AG | N/A | 428.50M |
Related stock screener links
About DBV.PA
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES FR
Employees: 110
Phone: 33155427878
DBV TECHNOLOGIES SA / DBV.PA FAQ
What does DBV do?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Can you provide the latest stock price for DBV TECHNOLOGIES SA?
The current stock price of DBV.PA is 2.285 EUR. The price decreased by -8.6% in the last trading session.
Does DBV stock pay dividends?
DBV.PA does not pay a dividend.
How is the ChartMill rating for DBV TECHNOLOGIES SA?
DBV.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of DBV stock?
DBV TECHNOLOGIES SA (DBV.PA) operates in the Health Care sector and the Biotechnology industry.
DBV.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DBV.PA. When comparing the yearly performance of all stocks, DBV.PA is one of the better performing stocks in the market, outperforming 99.24% of all stocks.
DBV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA. While DBV.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
DBV.PA Financial Highlights
Over the last trailing twelve months DBV.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| Debt/Equity | 0.08 |
DBV.PA Forecast & Estimates
8 analysts have analysed DBV.PA and the average price target is 3.98 EUR. This implies a price increase of 74.2% is expected in the next year compared to the current price of 2.285.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBV.PA